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 In an ecological study in this issue of  PLoS Medicine , Milane and colleagues found a temporal 
association between prescription of 
specifi c serotonin reuptake inhibitor 
(SSRI) antidepressants and suicide 
rates in the United States [1]. Their 
study addresses a subject of great 
public health importance and clinical 
interest. The researchers asked the 
question: was the use of antidepressants 
associated with a change in suicide 
rates in the general population of the 
United States between 1988 and 2002? 
There were two underlying hypotheses: 
(1) antidepressants can trigger suicide 
and subsequently increase suicide 
rates, and (2) through the treatment 
of depression with antidepressants, 
suicide rates decline over time.
 Methodology
 To address these hypotheses, the 
researchers conducted an ecological 
study drawing on aggregated data on 
suicide in the US general population 
between 1960 and 2002. These data 
were collected from the annual statistical 
fi les of the National Vital Statistics 
System compiled by the US Centers for 
Disease Control. Data on fl uoxetine 
prescription were obtained from IMS 
Health, a company that provides data 
on drug use to the pharmaceutical and 
health-care industries. 
 The authors estimated a potential 
effect of fl uoxetine on suicide rates 
by the use of a time-series regression 
model. They assumed a predicted 
suicide mortality in 1988–2002 based on 
maintained pre-1988 suicide trends, and 
considering fl uoxetine as a covariate for 
a potential effect on change of suicide 
rates between 1988 and 2002.
 Key Findings
 The authors reported that suicide 
rates were most prominent in the 
following two age groups: 15–24 and 
25–44 years of age (the upper age 
limit of the study population was 65 
years of age). The authors found 
that suicide rates fl uctuated between 
12.2 and 13.7 per 100,000 people 
for the entire population from the 
early 1960s until 1988, but then the 
rates gradually declined (in men and 
women), with the lowest value of 10.4 
per 100,000 people in the year 2000. 
They also found that the prescription 
of fl uoxetine inversely increased in 
relation to the trend in suicide rates 
from 1988 to 2002. This inverse 
relationship was highly correlated ( rs  = 
−0.92,  p < 0.001). 
 Milane and colleagues then modeled 
suicide rates in 1988–2002 based on 
pre-1988 suicide trends, and their 
modeling suggested that fl uoxetine 
prescription decreases suicides, both in 
women and in men. Further modeling 
analysis showed that if pre-1988 trends 
(i.e., trends in the pre-SSRI era) were 
extrapolated through 2002, suicide 
numbers would have been higher 
by about 33,600 cases. The authors 
summarized their fi ndings with the 
hypothesis that SSRIs may have saved 
33,600 lives since their introduction. 
 Strengths and Limitations 
of the Study
 The main strength of this study is the 
authors’ effort to address the crucial 
question of whether antidepressants 
do harm or good at a population level. 
Unfortunately, a research question 
such as this is not easy to answer. 
 As the authors acknowledge, 
suggestions that there may be a causal 
relationship between fl uoxetine 
prescription and suicide rates would 
represent an overinterpretation of the 
results. In a study like this, it is also 
important to consider other potential 
explanations for the fall in suicide 
rates, such as improvements in the 
economy or improved management of 
depression by primary-care providers. 
Moreover, as the study did not include 
people above 65 years of age, who are 
known to have an increased risk of 
suicide (especially in men) compared 
with younger people, the fi ndings are 
limited to adults up to 65 years of age. 
 Another limitation of this study was 
the use of fl uoxetine as a model of 
SSRI use. Several effective SSRIs have 
been introduced since the arrival of 
fl uoxetine, and these newer SSRIs may 
have had an additional potential impact 
on suicide rates. Finally, although the 
authors used the best available data 
on the number of prescriptions of 
fl uoxetine, these estimations are not 
 Suicide Rates and Antidepressant 
Prescribing: A Casual or Causal Relationship? 
Bernhard Baune, Phillipa Hay*
 Funding: The authors received no specifi c funding 
for this article. 
 Competing Interests: PH has received 
reimbursement costs of attending symposia from 
Solvay Pharmaceuticals, Bristol-Myers Squibb, and 
Pfi zer Pharmaceuticals, and Jansenn-Cilag. She has 
received honoraria (less than US$1,000 from each) for 
educational training of family doctors from Bristol-
Myers Squibb, Pfi zer Pharmaceuticals, Lundbeck, and 
Astra-Zeneca. BB has received reimbursement costs 
of attending congresses from AstraZeneca, Bristol-
Meyer Squibb, and Pfi zer Pharmaceuticals. He has 
received honoraria (less than US$1,000 from each) 
for educational training of general practitioners from 
Lundbeck, Astra-Zeneca, and Pfi zer Pharmaceuticals.
 Citation: Baune B, Hay P (2006) Suicide rates and 
antidepressant prescribing: A casual or causal 
relationship? PLoS Med 3(6): e220. DOI: 10.1371/
journal.pmed.0030220
 DOI: 10.1371/journal.pmed.0030220
 Copyright: © 2006 Baune and Hay. This is an 
open-access article distributed under the terms 
of the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original 
author and source are credited. 
 Abbreviation: SSRI, serotonin reuptake inhibitor 
 Bernhard Baune and Phillipa Hay are in the Discipline 
of Psychiatry, School of Medicine, James Cook 
University, Queensland, Australia.
 * To whom correspondence should be addressed. 
E-mail: phillipa.hay@jcu.edu.au 
 There was an inverse 
correlation between 
suicide rates and 
fl uoxetine prescriptions. 
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very accurate in terms of actual intake 
of antidepressants. As there are no 
reliable fi gures available on adherence 
to drug prescriptions at the population 
level, the real effect of antidepressants 
on suicide rates is diffi cult to estimate. 
 Implications for Clinicians and 
Policymakers
 Clinicians may be tempted to conclude 
from the study that the use of SSRIs 
leads to a decrease in depression 
and, subsequently, to a decrease of 
suicide attempts in their patients. 
Policymakers might prioritize the use 
of antidepressants at both primary 
and secondary health-care levels, 
assuming from the study that these 
drugs improve the lives of people with 
depression. 
 But an alternate view of the 
results is that they do not contribute 
substantial new knowledge and have 
no major clinical implications, since 
the effectiveness of antidepressants 
at improving depression is well 
established [2] (and there is some 
evidence of their potential to decrease 
suicide rates [3,4]). Moreover, it 
is questionable if a cross-sectional 
ecological study has the potential 
to adequately address the authors’ 
central research question of whether 
antidepressants do harm or good 
at a population level. In general, 
ecological and cross-sectional studies 
are suitable for generating new 
hypotheses and study questions, 
but not to answer analytic research 
questions as such. 
 Conclusion
 In our view, the single conclusion 
that can be drawn from this study is 
that there was an inverse correlation 
between suicide rates and fl uoxetine 
prescriptions. Thus, the study does 
not support an association between 
increased suicide and increased 
fl uoxetine prescription rates. This 
fi nding is of public health importance 
and should stimulate further scientifi c 
endeavors, in particular ecological 
research with a longitudinal design 
that considers additional factors such 
as economic data and a wider range of 
antidepressants with a potential impact 
on depression and suicide.  
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